Palvella Therapeutics (PVLA) Liabilities and Shareholders Equity (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $263.8 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 232.03% year-over-year to $263.8 million in Q1 2026; TTM through Mar 2026 was $464.0 million, a 117.59% increase from a year earlier, with the FY2025 full-year figure at $59.6 million, down 32.5% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $263.8 million, up from $59.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PVLA reached as high as $263.8 million in Q1 2026 and fell as low as $7.5 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $81.7 million across 5 years, with a median of $79.4 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity slumped 92.1% in 2023 and soared 1068.97% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $95.5 million in 2022, then slumped by 92.1% to $7.5 million in 2023, then surged by 1068.97% to $88.2 million in 2024, then tumbled by 32.5% to $59.6 million in 2025, then soared by 342.85% to $263.8 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $263.8 million in Q1 2026, $59.6 million in Q4 2025, and $66.9 million in Q3 2025.